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Objectives. We sought to 1) determine the proportion of appro-
priate elderly patients admitted to the hospital with unstable
angina who are treated with aspirin and heparin; 2) identify
patient factors associated with the Agency for Health Care Policy
and Research (AHCPR) guideline-based use of aspirin and hep-
arin; and 3) compare practice patterns and patient outcomes
before and after publication of the AHCPR guidelines.
Background. Improving the care of patients with unstable
angina may provide immediate opportunities to mitigate the
adverse consequences of unstable angina. However, despite the
importance of this diagnosis, there is a paucity of information on
the patterns of treatment and outcomes across diverse sites and
recent trends in practice that have occurred, especially since the
publication of the AHCPR practice guidelines.
Methods. We performed a retrospective cohort study using data
created from medical charts and administrative files. The sample
included 300 consecutive patients admitted to one of three Con-
necticut hospitals in the period 1993 to 1994 and 150 consecutive
patients admitted in 1995 with a principal discharge diagnosis of
unstable angina or chest pain.
Results. Of the 384 patients >265 years old who had no contrain-
dications to aspirin on hospital admission, 276 (72%) received it. Of
the 369 patients >265 years old who had no contraindications to
heparin on admission, 88 (24%) received it. Among the 321 patients
>265 years old who had no contraindications to aspirin at hospital
discharge, 208 (65%) were prescribed it. When 1995 was compared
with 1993 to 1994, the use of aspirin (odds ratio [OR] 2.3, 95%
confidence interval [CI] 1.3 to 4.0) and heparin (OR 2.8, 95% CI 1.6
to 4.9) on hospital admission significantly increased, and the use of
aspirin at discharge (OR 1.4, 95% CI 0.8 to 2.4) increased. Concom-
itantly, there was a significant reduction in 30-day readmission (OR
0.52, 95% CI 0.27 to 0.99).
Conclusions. Our results indicate an improvement in the care
and outcomes of elderly patients with unstable angina, but there
remain opportunities for further improvement.
(J Am Coll Cardiol 1998;31:957–63)
©1998 by the American College of Cardiology
In May 1994, an expert panel convened by the Agency for
Health Care Policy and Research (AHCPR) published the
Clinical Practice Guideline for the care of patients with
unstable angina (1). The panel intended its guidelines, which
were publicized and distributed across the United States, to
decrease unnecessary variation in practice patterns by critically
evaluating the published medical data and endorsing specific
treatment strategies. The document’s strongest recommenda-
tions concern hospital admission and treatment with aspirin
and heparin for patients at intermediate or high risk of
complications. Patients at low risk of complications are con-
sidered suitable for outpatient management.
Improving the care of patients with unstable angina may
provide immediate opportunities to mitigate its adverse con-
sequences. However, despite the importance of this diagnosis,
there is a paucity of information on the patterns of treatment
and outcomes across diverse sites. Accordingly, we sought to
compare the practice patterns and outcomes for elderly pa-
tients with unstable angina admitted to the hospital. Older
patients represent more than half of all patients admitted with
this condition and are considered by the Guidelines to have at
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least an intermediate risk of an adverse outcome and thus to
merit hospital admission (1,2). Our specific aims were 1) to
determine the proportion of appropriate patients who were
treated with aspirin and heparin; 2) to identify patient factors
associated with the use of aspirin and heparin; and 3) to
compare practice patterns and patient outcomes before and
after the publication of the AHCPR Guideline.
Methods
Selection of quality indicators. Representatives from the
three participating hospitals and the Connecticut Peer Review
Organization convened to develop quality indicators based on
the AHCPR Clinical Practice Guideline (1). Consensus was
achieved for three quality indicators: the administration of
aspirin on hospital admission, heparin on admission and the
prescription of aspirin at hospital discharge. Each process was
evaluated in a restricted sample of patients who were consid-
ered to be ideal candidates for the intervention. For the
evaluation of aspirin on admission, we developed a restricted
cohort by excluding patients with the following contraindica-
tions: hemorrhagic disorder or bleeding, thrombocytopenia
(platelets ,100,000), anemia (hematocrit ,30%), allergy or
sensitivity to aspirin and terminal illness. Because this indicator
was used to evaluate the relatively short-term use of aspirin for
the treatment of an acute condition, we did not exclude
patients with minor contraindications. Similarly, for the use of
heparin, we excluded patients with a hemorrhagic disorder or
bleeding, thrombocytopenia (,100,000), anemia (,30%), pro-
thrombin time .14 s on admission, allergy or sensitivity to
heparin, terminal illness or current warfarin therapy. Finally,
for the use of aspirin at discharge, we excluded patients with
any of the aspirin contraindications on admission, creatinine
.3 mg/dl or the prescription of warfarin at discharge. In this
case, we broadened our exclusions because the use of aspirin at
discharge is intended to be long term for secondary prevention.
We also determined the proportion of patients treated with
intravenous heparin who achieved a therapeutic partial throm-
boplastin time (46 to 72 s) within 24 h of admission. The
therapeutic window was based on the recommendation of the
AHCPR Guideline (1).
Hospital selection. The three hospitals invited to partici-
pate in this project represented the range of facilities in
Connecticut: one had cardiac catheterization facilities and
cardiac surgery facilities; one had cardiac catheterization facil-
ities only; and one had no such facilities. The bed capacity of
the hospitals ranged from 85 to 700. All hospitals had intensive
care units and were staffed by cardiologists.
Study sample. From Medicare’s National Claims History
File, we identified patients with a principal discharge diagnosis
of unstable angina, coronary artery disease or chest pain
(International Classification of Diseases, Ninth Revision, Clin-
ical Modification [ICD-9-CM] codes 411.x, 413.x, 786.50] at the
three study hospitals. From the calendar year 1994, 100
consecutive patients with unstable angina were identified for
review. For institutions with less than 100 cases, cases from
1993 were also included. From the calendar year 1995, 50
consecutive patients with unstable angina were identified and
reviewed. Patients were excluded if the diagnosis of presumed
unstable angina could not be validated by medical record
review. The coding of unstable angina was considered correct
if the patient was admitted nonelectively for presumed isch-
emic heart disease (based on the admitting notes) and had
chest pain within 24 h of hospital admission. We excluded
patients who died within 6 h of presentation to the hospital or
were transferred within 6 h of presentation to the hospital.
Data sources. Medical record review. Medical records were
abstracted by trained nurses and medical record technicians.
The data that were abstracted included detailed demographic,
clinical and process of care information. These data were
abstracted directly into standardized forms and then entered
into a computerized data base. Extensive training sessions and
detailed data definitions for each field were used to minimize
abstraction errors and variability. A random subsample of each
abstractor’s cases was reabstracted and assessed at weekly
team meetings to improve reliability.
Administrative data. The Health Care Financing Adminis-
tration’s (HCFA) MEDPAR file for Connecticut provided the
primary administrative data source for this analysis. This
publicly available file contains discharge abstracts for all
Medicare inpatients discharged from Connecticut hospitals
and was the source of information on readmission. In addition,
the Medicare Enrollment Database provided information on
mortality.
Variables. Variables included age, gender, race, history of
hypertension, diabetes, smoking, history of myocardial infarc-
tion, history of congestive heart failure, previous coronary
revascularization, history of stroke, history of chronic obstruc-
tive pulmonary disease, medications on admission, presence of
chest pain on admission, duration of symptoms before admis-
sion, presence of congestive heart failure on admission, vital
signs, admission laboratory tests (blood urea nitrogen, creati-
nine, hematocrit, PT), thrombolytic therapy on the first day,
shock, intubation and Killip class. Systolic blood pressure,
pulse and respiratory rate were taken as the highest value
recorded within 24 h of admission. Renal dysfunction was
defined as blood urea nitrogen .40 mg/dl or creatinine
.2.0 mg/dl. Only the electrocardiogram (ECG) in the first
period (1993 to 1994) was interpreted by a physician. Outcome
variables included aspirin and intravenous heparin on admis-
sion and aspirin at discharge. All admission and discharge
Abbreviations and Acronyms
AHCPR 5 Agency for Health Care Policy and Research
aPTT 5 activated partial thromboplastin time
CI 5 confidence interval
ECG 5 electrocardiogram, electrocardiographic
HCFA 5 Health Care Financing Administration
ICD 5 International Classification of Diseases
OR 5 odds ratio
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medications were reviewed for the use of aspirin (all formula-
tions were considered). Heparin that was administered for
prevention of deep vein thrombosis or for intravenous flushes
(dose #12,000 U/day) was not considered to be for systemic
heparinization. Other outcome variables included mortality
within 30 days of admission and readmission within 30 days of
discharge.
Statistical analysis. First, we created analytic programs to
represent the logic of each of the quality indicators. The results
are presented for the entire cohort and by hospital. Second, we
evaluated the bivariate association between the appropriate
treatment of patients eligible for each quality indicator and a
constellation of variables that included demographic (age,
gender and race), clinical (coronary artery disease risk factors,
past medical history, cardiac medications on admission, cardiac
history and acuity of presentation) and ECG characteristics.
Then we developed stepwise logistic regression models to
identify factors independently associated with satisfactory per-
formance on each indicator. Candidate variables were selected
from the variables identified in the bivariate analysis as having
an association at p , 0.10 or clinical relevance, or both. All
models were constructed with an entry significance level of 0.01
and an exit significance level of 0.05.
Next, we compared the performance of the quality indica-
tors in 1993 to 1994 to those in 1995 using the chi-square test.
We also repeated the logistic regression models and forced in
an indicator for the time period. We selected the sample size to
be able to detect moderate (or larger) differences in the use of
aspirin and heparin between the periods. We estimated, for
example, that we would have .80% power to detect an
absolute change over time of 15% in the use of aspirin (from
60% to 75%) or heparin (from 20% to 35%).
Finally, we evaluated 30-day mortality and readmission in
the two periods, unadjusted and after adjusting for age, Killip
class, diabetes mellitus and renal function. For all models, we
constructed and examined partial residual plots to evaluate
potential problematic areas of model fit (3). Goodness of fit
was also evaluated (4). In addition, we calculated an area
under the receiver operating curve for each model to evaluate
the discriminating power of the fitted model (5). For the
evaluation of aspirin at discharge, we repeated the analysis
after excluding patients with the principal discharge diagnosis
code of chest pain (ICD-9-CM code 786.50), because these
patients may not be known or considered to have coronary
artery disease.
Results
Study sample. There were 450 patients who met the crite-
ria for the study sample, including 300 in the first period
(1993–1994) and 150 in the second period (1995). The most
common principal discharge diagnosis for the cohort was 411.1
(54.2%), followed by 786.50 (33.6%), 413.9 (11.6%), 411.81
(0.2%) and 411.89 (0.4%).
The demographic and preadmission characteristics of the
study sample are shown in Table 1. The patients were elderly
(mean age 76.4 6 7.3 years, median 76, range 65 to 100) and
predominately female (64.4%). The majority of the patients
had a history of coronary artery disease, as indicated by a
history of angina (69.8%) or myocardial infarction (34.4%);
43.1% of patients were taking aspirin as a preadmission
medication.
Overall, the patients were hemodynamically stable. Only
one of the patients was considered to be in shock. A total of 69
patients (15.3%) had a heart rate .100 beats/min; 16 (4%) had
a respiratory rate .30 breaths/min; and 36 (8%) had a systolic
blood pressure ,125 mm Hg. Heart failure was present in 79
patients (18%). No patient required ventilatory support. The
initial ECG was interpreted as normal for 51 of the cohort
(17%) from the first period. For 43% of these patients, the
ECG was obtained within 20 min of presentation to the
hospital. The length of hospital stay for the study sample was
4.7 6 2.8 days. The readmission rate within 30 days of
discharge was 15%, and the mortality rate within 30 days of
admission was 2%.
When the two periods were compared, there were no
substantial or significant differences in demographic character-
istics. From a clinical perspective, the patients in the second
period were less likely to have a history of angina, myocardial
infarction, heart failure or reperfusion therapy. However, the
patients in the second period had a similar preadmission use of
aspirin. The length of hospital stay for the first period was
5.1 6 3.1 days compared with 4.0 6 1.9 days in the second
period (p , 0.001).
Aspirin on admission. Of the 450 patients in the sample,
384 were considered ideal candidates for the acute use of
aspirin. Of these patients, 276 (72%) received it (Tables 2 and
3). Performance of this quality indicator varied across the
hospitals from 66% to 77%. The use of aspirin on admission in
the ideal group increased significantly over the two periods,
from 66% to 82% (p , 0.001) (Table 3). The absolute increase
at the hospitals ranged from 8% to 27%. Adjusting for baseline
differences between the groups, the odds ratio (OR) increase
in the use of aspirin in 1995 compared with 1993 to 1994 was
2.31 (95% confidence interval [CI] 1.32 to 4.03). Other factors
that were associated with performance of this quality indicator
included aspirin as a preadmission medication (OR 3.0, 95%
CI 1.7 to 5.0), history of heart failure (OR 0.4, 95% CI 0.2 to
0.8), history of renal disease (OR 0.6, 95% CI 0.3 to 1.0) and
preadmission use of warfarin (OR 0.2, 95% CI 0.1 to 0.4).
Heparin on hospital admission. Of the 450 patients in the
sample, 369 were considered ideal candidates for intravenous
heparin on admission. Of these patients, 89 (24%) received it
(Table 2). Performance of this quality indicator varied across
the hospitals from 10% to 43%. The use of heparin increased
significantly over the two periods, from 20% to 32% (p , 0.01)
(Table 3). The absolute change at the hospitals ranged from
25% to 29%. After baseline differences between the groups
were adjusted, the OR increase in the use of heparin among
the ideal patients was 2.83 (95% CI 1.64 to 4.89). Other factors
that were associated with satisfactory performance of this
quality indicator included tachycardia (OR 2.1, 95% CI 1.1 to
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Table 1. Hospital Admission Characteristics of the Study Sample
Characteristic
Total
(n 5 450)
1993–1994
(n 5 300)
1995
(n 5 150) p Value*
Age group (yr)
65–74 190 (42%) 126 (42%) 64 (43%) 0.9
75–84 195 (43%) 135 (45%) 60 (40%) 0.3
$85 65 (14%) 39 (13%) 26 (17%) 0.2
Female gender 290 (64%) 186 (62%) 104 (69%) 0.1
White race 398 (88%) 261 (87%) 137 (91%) 0.2
Cardiac risk factor
Hx of HTN 276 (61%) 190 (63%) 86 (57%) 0.2
DM 106 (24%) 77 (26%) 29 (19%) 0.1
Current smoker 43 (10%) 33 (11%) 10 (7%) 0.1
Cardiac history
UA 314 (70%) 233 (78%) 81 (54%) , 0.001
MI 155 (34%) 117 (39%) 38 (25%) 0.004
CHF 79 (18%) 62 (21%) 17 (11%) 0.01
PTCA 43 (10%) 33 (11%) 10 (7%) 0.1
CABG 69 (15%) 51 (17%) 18 (12%) 0.2
Medical history
Stroke 58 (13%) 40 (13%) 18 (12%) 0.7
PVD 61 (14%) 44 (15%) 17 (11%) 0.3
COPD 83 (18%) 61 (20%) 22 (15%) 0.1
Peptic ulcer disease 6 (1%) 6 (2%) 0 0.2
Liver disease 7 (2%) 6 (2%) 1 (0.7%) 0.3
Bleeding within 1 yr 14 (3%) 10 (3%) 4 (3%) 0.7
Dementia 17 (4%) 13 (4%) 4 (3%) 0.4
Metastatic cancer 81 (18%) 58 (19%) 23 (15%) 0.3
Terminal illness 0 0 0 —
Preadmission meds
Aspirin 194 (43%) 131 (44%) 63 (42%) 0.7
Nitrates 213 (47%) 154 (51%) 59 (39%) 0.02
BBs 128 (28%) 85 (28%) 43 (29%) 0.9
CCBs 192 (43%) 141 (47%) 51 (34%) 0.009
Digoxin 92 (20%) 66 (22%) 26 (17%) 0.2
ACE I 89 (20%) 54 (18%) 35 (23%) 0.2
Loop diuretic 131 (29%) 93 (31%) 38 (25%) 0.2
Warfarin 36 (8%) 27 (9%) 9 (6%) 0.3
Chest pain
Present on presentation 279 (62%) 178 (59%) 101 (67%) 0.3
Duration .6 h 112 (25%) 73 (24%) 39 (26%) 0.7
Killip class 1 321 (71%) 201 (67%) 120 (80%) 0.004
Initial vital sign
Pulse .100 bpm 69 (15%) 50 (17%) 19 (13%) 0.3
RR .30 breaths/min 16 (4%) 16 (5%) 0 0.004
SBP ,125 mm Hg† 36 (8%) 14 (5%) 22 (15%) , 0.001
ECG obtained within 20 min N/A 128 (43%) N/A —
Admission lab results
BUN .40 mg/dl or creatinine .2.5 mg/dl 30 (7%) 25 (8%) 5 (3%) 0.04
Hct ,30% 27 (6%) 23 (8%) 4 (3%) 0.03
PTT .16 s 24 (5%) 19 (6%) 5 (3%) 0.2
Shock within 24 h of admission 1 (0.2%) 1 (0.3%) 0 0.5
Intubation within 24 h of admission 0 0 0 —
*For comparison of time periods. †Highest systolic blood pressure (SBP) within 24 h. Data presented are number (%)
of patients. ACE I 5 angiotensin-converting enzyme inhibitor; BBs 5 beta-blockers; bpm 5 beats per minute; BUN 5
blood urea nitrogen; CABG 5 coronary artery bypass graft surgery; CCBs 5 calcium channel blockers; CHF 5
congestive heart failure; COPD 5 chronic obstructive pulmonary disease; DM 5 diabetes mellitus; ECG 5 electrocar-
diogram; HTN 5 hypertension; Hx 5 history; lab 5 laboratory; meds 5 medications; MI 5 myocardial infarction; N/A 5
not applicable; PTT 5 prothrombin time; PTCA 5 percutaneous transluminal coronary angiography; PVD 5 peripheral
vascular disease; RR 5 respiratory rate; UA 5 unstable angina.
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4.1), history of bypass surgery (OR 2.5, 95% CI 1.3 to 4.9),
history of angioplasty (OR 2.9, 95% CI 1.3 to 6.6), Killip class
1 or 2 (OR 2.3, 95% CI 1.3 to 3.9) and history of hypertension
(OR 2.0, 95% CI 1.2 to 3.4).
Of those patients receiving heparin, 51% had a therapeutic
activated partial thromboplastin time (aPTT) within 24 h. The
rate across hospitals ranged from 28% to 58%. Sixteen percent
had an aPTT .100 s within the first 24 h, and 5% never
achieved an aPTT .46 s. In the second period there was no
significant increase in the proportion of patients who achieved
a therapeutic aPTT.
Aspirin at hospital discharge. Of the 321 patients consid-
ered ideal candidates for the prescription of aspirin at dis-
charge, 209 (65%) received it (Table 2). Performance of this
quality indicator varied across the hospitals from 58% to 72%.
The prescribed use of aspirin at discharge slightly increased
over the two periods, from 63% to 68% (p 5 0.7) (Table 3).
The absolute change at the hospitals ranged from 23% to
16%. After baseline differences between the groups were
adjusted, the OR increase in the use of aspirin was 1.39 (95%
CI 0.80 to 2.43). Other factors that were associated with
performance of this quality indicator included aspirin as a
preadmission medication (OR 5.2, 95% CI 2.9 to 9.5), history
of chronic angina (OR 2.8, 95% CI 1.6 to 4.9), stress test (OR
2.8, 95% CI 1.6 to 5.1), history of stroke or transient ischemic
attack (OR 3.3, 95% CI 1.1 to 9.8), Killip class 1 or 2 (OR 0.5,
95% CI 0.3 to 0.9) or tachypnea on presentation (OR 0.1, 95%
CI 0.2 to 0.8).
After the patients who were coded with a principal dis-
charge diagnosis of 786.50 (chest pain) were excluded, there
remained 200 patients who were ideal candidates for aspirin at
hospital discharge. Of this group, 139 (70%) were prescribed
aspirin. The prescribed use of aspirin at discharge increased
over the two periods, from 66% to 79% (p 5 0.09). The
absolute increase at the hospitals ranged from 4% to 20%.
After adjustment of baseline differences between the groups,
the OR increase in the use of aspirin was 2.10 (95% CI 0.91 to
5.01).
Clinical outcomes. The 30-day readmission rate for the
first period was 18% compared with 9% in the second period
(p 5 0.03). The 30-day mortality rate for the first period was
2.3% compared with 1.0% in the second period (p 5 0.2).
After age, Killip class, diabetes mellitus and renal function
were adjusted, the OR decrease in 30-day mortality from the
1993 to 1994 period to 1995 was 0.49 (95% CI 0.05 to 5.00),
and the OR decrease in 30-day readmission was 0.52 (95% CI
0.27 to 0.99).
Discussion
We measured the quality of care between 1993 to 1994 and
1995 for elderly Medicare beneficiaries discharged from the
hospital with a principal discharge diagnosis code consistent
with unstable angina, and we found improvement in adherence
to the best practices described by the AHCPR Guideline. We
also found potential opportunities for improvement in the care
of these patients. Our evaluation of consecutive patients
admitted to three Connecticut hospitals over two periods with
unstable angina revealed that 28% of appropriate patients did
not receive aspirin on hospital admission, 76% did not receive
heparin on admission and 35% were not prescribed aspirin at
discharge.
Patients may not receive treatment which the Guideline
states as optimal, either because of mere oversight or deliberate
rejection of the recommendations of the expert panel. Clinical
trial data supporting the use of these therapies preceded the
Table 2. Use of Aspirin and Heparin on Hospital Admission and Aspirin at Discharge Among Patients Without Contraindications
Aspirin on Admission Aspirin at Discharge Heparin on Admission
No. of Pts Without
Contraindications
No. (%) of Pts
Treated
No. of Pts Without
Contraindications
No. (%) of Pts
Treated
No. of Pts Without
Contraindications
No. (%) of Pts
Treated
Hospital A 122 94 (77%) 113 65 (58%) 121 23 (20%)
Hospital B 129 94 (73%) 101 73 (72%) 126 13 (10%)
Hospital C 133 88 (66%) 107 71 (66%) 122 53 (43%)
Total 384 276 (72%) 321 209 (65%) 369 89 (24%)
Pts 5 patients.
Table 3. Use of Aspirin and Heparin on Hospital Admission and Aspirin at Discharge Among Patients Without Contraindications by
Time Period
Aspirin on Admission Aspirin at Discharge Heparin on Admission
1993–1994 1995 p Value 1993–1994 1995 p Value 1993–1994 1995 p Value
Hospital A 74% 82% 0.3 59% 56% 0.9 21% 16% 0.6
Hospital B 69% 80% 0.2 71% 75% 0.3 5% 20% 0.008
Hospital C 57% 84% 0.002 61% 77% 0.3 34% 63% 0.003
Total 66% 82% 0.001 63% 68% 0.7 20% 32% 0.01
Data presented are percent of patients.
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first study period, but some physicians may not have been
aware of these studies or were not persuaded by them. In a
recent study, many physicians, especially noncardiologists,
were not confident about the benefit of several interventions,
including aspirin, that had been demonstrated to be efficacious
in clinical trials and endorsed by practice guidelines for the
treatment of acute myocardial infarction (6).
The varied inclusion and exclusion criteria employed in
trials of unstable angina may have raised concerns about
generalizability and may have deterred some physicians from
treating patients with the appropriate therapy (7–13). Unstable
angina defies easy categorization and may comprise an ex-
tremely broad range of clinical conditions. Although the
Guideline attempted to address this issue by creating criteria
for risk stratifying a broad range of patients, the acceptance of
this approach is not known.
To understand why the care of some patients may deviate
from the Guideline’s recommendations, we identified the
factors independently associated with the decision not to treat
patients with aspirin and heparin on admission and aspirin at
discharge. No unifying explanation emerged from this analysis
because different factors related to each of the indicators. As
expected, the previous use of aspirin was predictive of its use
on admission and at discharge. Patients with known coronary
artery disease, as evidenced by previous revascularization,
were more likely to receive heparin. Neither age nor gender
was associated with performance of any of the indicators.
Adherence to the Guideline recommendations for all three
indicators was higher in the second period, suggesting that the
recent attention to quality improvement and the dissemination
of information on unstable angina through the efforts of the
AHCPR and other organizations may have had a salutary
effect. The Guideline, which distilled the information available
in the published medical data into several recommendations
and treatment algorithms, was widely publicized. More than
500,000 copies were distributed to health care providers
around the country. Between 1993 to 1994 and 1995, contem-
poraneous with the publication of the AHCPR Guideline,
there was a marked improvement in the process of care for
patients with unstable angina. This change in practice occurred
even though the information on which the specific recommen-
dations about aspirin and heparin were based had been
available for several years. In particular, the use of aspirin on
presentation improved dramatically. Although these data can-
not prove a causal relation, they do demonstrate an improve-
ment in the process of care during a period in which leaders in
cardiology focused their attention on defining and improving
the optimal care of this condition.
Despite the improvement in care, the use of heparin
remained low. The explanation for this practice may involve
the perception of the patient’s risk. Although the Guideline
places elderly patients into at least the intermediate risk
category on the basis of age alone, we found that elderly
patients admitted with unstable angina in actual clinical prac-
tice had fairly low risk characteristics aside from their age. Few
of these patients had tachycardia, tachypnea or hypotension,
and one-fifth had a normal ECG on presentation. The mortal-
ity rate for the group was only 2%. Unstable angina is
commonly considered a high risk condition, but our data
suggest that many of these patients may not have had a high
risk ischemic syndrome.
The recognition by treating physicians of a low risk sub-
group of elderly patients may explain why clinical practice
occasionally deviates from the recommendations of the expert
panel. The Guideline indicated that patients .65 years old and
meeting criteria for the diagnosis of unstable angina merit
hospital admission. However, if many older patients with
criteria for unstable angina are truly at low risk, despite their
age, then the Guideline would not support a decision to admit
and initiate heparin therapy, but would commend outpatient
management as it does for younger low risk patients. It is
therefore possible that clinicians who admitted elderly patients
with unstable angina according to local standards recognized
many of these patients as having a low risk of adverse outcomes
and, accordingly, withheld heparin.
Among the patients who did begin heparin therapy, many
did not reach the target levels of anticoagulation cited by the
AHCPR Guideline within 24 h of the initiation of therapy. This
finding has been observed by other investigators and demon-
strates that an assessment of the use of heparin needs to be
supplemented by information about whether it is being given in
the proper dose (14). Determining merely whether heparin
was used does not truly indicate the adequacy of therapy,
because even patients who satisfy the quality indicator for
heparin may not be therapeutically anticoagulated. This find-
ing also identifies an area for improvement. Hospitals need to
develop better strategies to achieve therapeutic anticoagula-
tion, such as the use of weight-based heparin dosing (15).
Finally, there was a clear association between the site of
care and the use of medications. With such a small number of
hospitals, the stratification of results by hospital characteristics
would obviously reveal their identities and violate our confi-
dentiality agreement. We can note, however, that marked
differences occurred and may represent cultures and processes
particular to each institution. Hospitals cooperated in this
project to identify ways to ameliorate quality of care and are
already embarking on quality improvement initiatives.
Although this study focused on process of care as a
surrogate for quality of care, it also included information on
outcome. The mortality rate of the patients admitted to the
hospital during the first period was higher than that in the
second period. With the small number of events, the study was
not adequately powered to detect a significant difference. The
nonsignificant difference in the mortality rate in the face of an
improvement in process illustrates the difficulty of focusing
solely on outcomes as a measure of quality, because each
improvement in process does not translate directly into an
improvement in outcome. Because many patients must be
treated with an efficacious medical strategy to save even one
life, a relatively small sample size may limit our ability to detect
differences in mortality in a single institution or several insti-
tutions. However, for these patients, a more important out-
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come may be the readmission rate within 30 days. The
readmission rate of the patients admitted to the hospital
during the first period was significantly higher than that in the
second period, even after adjusting for baseline differences.
Although this difference cannot be attributed to the change in
process, it was reassuring to observe improvements in process
and outcome tracking together. Nevertheless, the observed
decrease in readmissions is larger than what would have been
expected from the improvements in process alone.
Study limitations. This study has several limitations: 1)
The information was collected by retrospective chart review
and is dependent on the quality of the record-keeping. How-
ever, the medications, which constitute the most important
variables, were well documented in the hospital record. 2) The
identification of cases was dependent on coding of the princi-
pal discharge diagnosis. To improve the sensitivity of our case
ascertainment, we included a broad range of codes and vali-
dated the diagnosis by chart review. To improve specificity, we
excluded patients admitted for an elective procedure or those
who did not have chest pain consistent with ischemia within
24 h of admission. 3) Our study was restricted to three
hospitals, although we did include a range of facilities. 4) The
sample size is another limitation. We had the power to detect
moderate improvements in the process of care. Aspirin and
heparin on hospital admission showed marked improvement,
and the differences over time were significant. The improve-
ment in aspirin at hospital discharge was more modest and did
not reach statistical significance. This result may have been
statistically significant with a larger number of patients. Also,
given the relatively small number of outcome events, we could
not quantify precisely the association between the improve-
ments in process and the improvements in the clinical out-
comes. A much larger sample size or a much higher event rate
would have been necessary to examine this issue. Despite these
limitations, this study provides a first step toward addressing
the remarkable dearth of information on the actual care of
elderly patients with unstable angina.
Conclusions. This study indicates the progress toward bet-
ter treatment of patients with unstable angina and the chal-
lenges for the future. Improvement in adherence to the best
practice is occurring, but there remain patients who do not
receive care that is consistent with the practice guidelines. The
reasons for the lack of adherence to the recommendations and
their implications on patient outcomes need further investiga-
tion. The low event rate in this group suggests that some
elderly patients with symptoms consistent with an ischemic
syndrome may be stratified as low risk, thus avoiding hospital
admission.
We are indebted to the many individuals from the Connecticut Peer Review
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